snake venom-derived natriuretic peptide (University of Sydney/Oxydend Therapeutics)

N/A

Report date: 2025/03/20 09:53:41

Base Information

Drug Namesnake venom-derived natriuretic peptide (University of Sydney/Oxydend Therapeutics)
Drug Alias NameTDT (Oxydend)
ClassificationBiologics
Mechanisms of ActionNatriuretic peptide receptor 1 agonistsAtrial natriuretic peptide receptor type B agonists
TargetsAtrial natriuretic peptide receptor type BNatriuretic peptide receptor 1
Therapy Area/IndicationsHeart Failure
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity of Sydney
China Registration ClassN/A

Develop Information

Active CompaniesOxydend Therapeutics Pty LtdUniversity of Sydney
Inactive CompaniesN/A
Active IndicationsHeart Failure
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A